Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B.

Couto E, Diaz-Brito V, Mothe B, Guardo AC, Fernandez I, Ugarte A, Etcheverry F, Gómez CE, Esteban M, Pich J, Arnaiz JA, López Bernaldo de Quirós JC, Brander C, Plana M, García F, Leal L.

Vaccines (Basel). 2019 Nov 7;7(4). pii: E178. doi: 10.3390/vaccines7040178.

2.

Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Kilpeläinen A, Saubi N, Guitart N, Olvera A, Hanke T, Brander C, Joseph J.

Vaccines (Basel). 2019 Aug 2;7(3). pii: E78. doi: 10.3390/vaccines7030078.

3.

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).

Mothe B, Manzardo C, Sanchez-Bernabeu A, Coll P, Morón-López S, Puertas MC, Rosas-Umbert M, Cobarsi P, Escrig R, Perez-Alvarez N, Ruiz I, Rovira C, Meulbroek M, Crook A, Borthwick N, Wee EG, Yang H, Miró JM, Dorrell L, Clotet B, Martinez-Picado J, Brander C, Hanke T.

EClinicalMedicine. 2019 Jun 5;11:65-80. doi: 10.1016/j.eclinm.2019.05.009. eCollection 2019 May-Jun.

4.

Can we just kick-and-kill HIV: possible challenges posed by the epigenetically controlled interplay between HIV and host immunity.

Ruiz-Riol M, Brander C.

Immunotherapy. 2019 Aug;11(11):931-935. doi: 10.2217/imt-2019-0092. Epub 2019 Jun 20. No abstract available.

5.

iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.

de Jong W, Aerts J, Allard S, Brander C, Buyze J, Florence E, van Gorp E, Vanham G, Leal L, Mothe B, Thielemans K, Plana M, Garcia F, Gruters R; iHIVARNA consortium.

Trials. 2019 Jun 17;20(1):361. doi: 10.1186/s13063-019-3409-1.

6.

Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles.

Tumiotto C, Alves BM, Recordon-Pinson P, Jourdain M, Bellecave P, Guidicelli GL, Visentin J, Bonnet F, Hessamfar M, Neau D, Sanchez J, Brander C, Sajadi M, Eyzaguirre L, Soares EA, Routy JP, Soares MA, Fleury H.

PLoS One. 2019 Feb 27;14(2):e0212347. doi: 10.1371/journal.pone.0212347. eCollection 2019.

7.

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.

Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

PLoS One. 2018 Dec 19;13(12):e0208345. doi: 10.1371/journal.pone.0208345. eCollection 2018.

8.

Zip6 Transporter Is an Essential Component of the Lymphocyte Activation Machinery.

Colomar-Carando N, Meseguer A, Company-Garrido I, Jutz S, Herrera-Fernández V, Olvera A, Kiefer K, Brander C, Steinberger P, Vicente R.

J Immunol. 2019 Jan 15;202(2):441-450. doi: 10.4049/jimmunol.1800689. Epub 2018 Dec 14.

PMID:
30552163
9.

Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.

Rosás-Umbert M, Llano A, Bellido R, Olvera A, Ruiz-Riol M, Rocafort M, Fernández MA, Cobarsi P, Crespo M, Dorrell L, Del Romero J, Alcami J, Paredes R, Brander C, Mothe B.

J Virol. 2019 Feb 5;93(4). pii: e01436-18. doi: 10.1128/JVI.01436-18. Print 2019 Feb 15.

10.

Strong sex bias in elite control of paediatric HIV infection.

Vieira VA, Zuidewind P, Muenchhoff M, Roider J, Millar J, Clapson M, Van Zyl A, Shingadia D, Adland E, Athavale R, Grayson N, Ansari MA, Brander C, Guash CF, Naver L, Puthanakit T, Songtaweesin WN, Ananworanich J, Peluso D, Thomé B, Pinto J, Jooste P, Tudor-Williams G, Cotton MF, Goulder P.

AIDS. 2019 Jan 27;33(1):67-75. doi: 10.1097/QAD.0000000000002043.

11.

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection.

Leal L, Guardo AC, Morón-López S, Salgado M, Mothe B, Heirman C, Pannus P, Vanham G, van den Ham HJ, Gruters R, Andeweg A, Van Meirvenne S, Pich J, Arnaiz JA, Gatell JM, Brander C, Thielemans K, Martínez-Picado J, Plana M, García F; iHIVARNA consortium.

AIDS. 2018 Nov 13;32(17):2533-2545. doi: 10.1097/QAD.0000000000002026. Erratum in: AIDS. 2019 Oct 1;33(12):1957.

12.

Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection.

Guillén Y, Noguera-Julian M, Rivera J, Casadellà M, Zevin AS, Rocafort M, Parera M, Rodríguez C, Arumí M, Carrillo J, Mothe B, Estany C, Coll J, Bravo I, Herrero C, Saz J, Sirera G, Torrella A, Navarro J, Crespo M, Negredo E, Brander C, Blanco J, Calle ML, Klatt NR, Clotet B, Paredes R.

Mucosal Immunol. 2019 Jan;12(1):232-246. doi: 10.1038/s41385-018-0083-7. Epub 2018 Aug 31.

PMID:
30171206
13.

HIV T-Cell Vaccines.

Mothe B, Brander C.

Adv Exp Med Biol. 2018;1075:31-51. doi: 10.1007/978-981-13-0484-2_2. Review.

PMID:
30030788
14.

Are patients being evaluated for periprosthetic joint infection prior to referral to a tertiary care center?

Tetreault MW, Estrera KA, Kayupov E, Brander C, Della Valle CJ.

Arthroplast Today. 2017 Nov 10;4(2):216-220. doi: 10.1016/j.artd.2017.10.001. eCollection 2018 Jun.

15.

HIV LTR-Driven Antisense RNA by Itself Has Regulatory Function and May Curtail Virus Reactivation From Latency.

Kobayashi-Ishihara M, Terahara K, Martinez JP, Yamagishi M, Iwabuchi R, Brander C, Ato M, Watanabe T, Meyerhans A, Tsunetsugu-Yokota Y.

Front Microbiol. 2018 May 25;9:1066. doi: 10.3389/fmicb.2018.01066. eCollection 2018.

16.

Early diagnosis of HIV infection among men who have sex with men in Lima (Peru). A prospective cohort study.

Coll J, Videla S, Ganoza C, Ornelas A, Pérez S, Clotet B, Brander C, Sánchez J.

Clin Microbiol Infect. 2018 Jul;24(7):793-795. doi: 10.1016/j.cmi.2018.02.029. Epub 2018 Mar 2. No abstract available.

17.

Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy In Vitro.

Olvera A, Martinez JP, Casadellà M, Llano A, Rosás M, Mothe B, Ruiz-Riol M, Arsequell G, Valencia G, Noguera-Julian M, Paredes R, Meyerhans A, Brander C.

Front Immunol. 2018 Jan 26;8:2010. doi: 10.3389/fimmu.2017.02010. eCollection 2017.

18.

Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection.

Adland E, Hill M, Lavandier N, Csala A, Edwards A, Chen F, Radkowski M, Kowalska JD, Paraskevis D, Hatzakis A, Valenzuela-Ponce H, Pfafferott K, Williams I, Pellegrino P, Borrow P, Mori M, Rockstroh J, Prado JG, Mothe B, Dalmau J, Martinez-Picado J, Tudor-Williams G, Frater J, Stryhn A, Buus S, Teran GR, Mallal S, John M, Buchbinder S, Kirk G, Martin J, Michael N, Fellay J, Deeks S, Walker B, Avila-Rios S, Cole D, Brander C, Carrington M, Goulder P.

J Virol. 2018 Jan 30;92(4). pii: e01685-17. doi: 10.1128/JVI.01685-17. Print 2018 Feb 15.

19.

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.

Rosás-Umbert M, Mothe B, Noguera-Julian M, Bellido R, Puertas MC, Carrillo J, Rodriguez C, Perez-Alvarez N, Cobarsí P, Gomez CE, Esteban M, Jímenez JL, García F, Blanco J, Martinez-Picado J, Paredes R, Brander C.

PLoS One. 2017 Sep 27;12(9):e0184929. doi: 10.1371/journal.pone.0184929. eCollection 2017.

20.

Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men.

Coll J, Videla S, Leon A, Ornelas A, García F, Fernández E, Blanco JL, Carrillo A, Bravo I, Meulbroek M, García-Cuyas F, González V, Casabona J, Leal L, Clotet B, Brander C; Check-Ear Project.

Clin Microbiol Infect. 2018 May;24(5):540-545. doi: 10.1016/j.cmi.2017.08.012. Epub 2017 Aug 24.

21.

Impact of HLA-DRB1 allele polymorphisms on control of HIV infection in a Peruvian MSM cohort.

Oriol-Tordera B, Llano A, Ganoza C, Cate S, Hildebrand W, Sanchez J, Calle ML, Brander C, Olvera A.

HLA. 2017 Oct;90(4):234-237. doi: 10.1111/tan.13085. Epub 2017 Jul 5.

PMID:
28677168
22.

Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for In Vivo HIV Control.

Ruiz-Riol M, Berdnik D, Llano A, Mothe B, Gálvez C, Pérez-Álvarez S, Oriol-Tordera B, Olvera A, Silva-Arrieta S, Meulbroek M, Pujol F, Coll J, Martinez-Picado J, Ganoza C, Sanchez J, Gómez G, Wyss-Coray T, Brander C.

J Virol. 2017 Jul 27;91(16). pii: e00441-17. doi: 10.1128/JVI.00441-17. Print 2017 Aug 15.

23.

Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines.

Borthwick N, Lin Z, Akahoshi T, Llano A, Silva-Arrieta S, Ahmed T, Dorrell L, Brander C, Murakoshi H, Takiguchi M, Hanke T.

PLoS One. 2017 Apr 27;12(4):e0176418. doi: 10.1371/journal.pone.0176418. eCollection 2017.

24.

Lymphocyte Activation Dynamics Is Shaped by Hereditary Components at Chromosome Region 17q12-q21.

Carreras-Sureda A, Rubio-Moscardo F, Olvera A, Argilaguet J, Kiefer K, Mothe B, Meyerhans A, Brander C, Vicente R.

PLoS One. 2016 Nov 11;11(11):e0166414. doi: 10.1371/journal.pone.0166414. eCollection 2016.

25.

Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix).

Guardo AC, Joe PT, Miralles L, Bargalló ME, Mothe B, Krasniqi A, Heirman C, García F, Thielemans K, Brander C, Aerts JL, Plana M; iHIVARNA consortium.

AIDS. 2017 Jan 28;31(3):321-332. doi: 10.1097/QAD.0000000000001276. Erratum in: AIDS. 2019 Oct 1;33(12):1957.

PMID:
27677160
26.

A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection.

Biasin M, Sironi M, Saulle I, Pontremoli C, Garziano M, Cagliani R, Trabattoni D, Lo Caputo S, Vichi F, Mazzotta F, Forni D, Riva S, Aguilar-Jimenez W, Cedeño S, Sanchez J, Brander C, Zapata W, Rugeles MT, Clerici M.

Microbes Infect. 2017 Jan;19(1):69-74. doi: 10.1016/j.micinf.2016.09.005. Epub 2016 Sep 18.

PMID:
27652980
27.

Gut Microbiota Linked to Sexual Preference and HIV Infection.

Noguera-Julian M, Rocafort M, Guillén Y, Rivera J, Casadellà M, Nowak P, Hildebrand F, Zeller G, Parera M, Bellido R, Rodríguez C, Carrillo J, Mothe B, Coll J, Bravo I, Estany C, Herrero C, Saz J, Sirera G, Torrela A, Navarro J, Crespo M, Brander C, Negredo E, Blanco J, Guarner F, Calle ML, Bork P, Sönnerborg A, Clotet B, Paredes R.

EBioMedicine. 2016 Jan 28;5:135-46. doi: 10.1016/j.ebiom.2016.01.032. eCollection 2016 Mar.

28.

Correction: Identification of Immunogenic Cytotoxic T Lymphocyte Epitopes Containing Drug Resistance Mutations in Antiretroviral Treatment-Naïve HIV-Infected Individuals.

Blanco-Heredia J, Lecanda A, Valenzuela-Ponce H, Brander C, Ávila-Ríos S, Reyes-Terán G.

PLoS One. 2016 Apr 5;11(4):e0153340. doi: 10.1371/journal.pone.0153340. eCollection 2016. No abstract available.

29.

Identification of Immunogenic Cytotoxic T Lymphocyte Epitopes Containing Drug Resistance Mutations in Antiretroviral Treatment-Naïve HIV-Infected Individuals.

Blanco-Heredia J, Lecanda A, Valenzuela-Ponce H, Brander C, Ávila-Ríos S, Reyes-Terán G.

PLoS One. 2016 Jan 25;11(1):e0147571. doi: 10.1371/journal.pone.0147571. eCollection 2016. Erratum in: PLoS One. 2016;11(4):e0153340.

30.

Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination.

Rallón N, Mothe B, Lopez Bernaldo de Quiros JC, Plana M, Ligos JM, Montoya M, Muñoz-Fernández MA, Esteban M, Garcia F, Brander C, Benito JM; RISVAC03 Study Group.

AIDS. 2016 Feb 20;30(4):553-62. doi: 10.1097/QAD.0000000000000966.

PMID:
26558724
31.

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.

Gómez CE, Perdiguero B, García-Arriaza J, Cepeda V, Sánchez-Sorzano CÓ, Mothe B, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, López Bernaldo de Quirós JC, Brander C, García F, Esteban M.

PLoS One. 2015 Nov 6;10(11):e0141456. doi: 10.1371/journal.pone.0141456. eCollection 2015.

32.

Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells.

Ternette N, Yang H, Partridge T, Llano A, Cedeño S, Fischer R, Charles PD, Dudek NL, Mothe B, Crespo M, Fischer WM, Korber BT, Nielsen M, Borrow P, Purcell AW, Brander C, Dorrell L, Kessler BM, Hanke T.

Eur J Immunol. 2016 Jan;46(1):60-9. doi: 10.1002/eji.201545890. Epub 2015 Nov 4.

33.

Variants in the CYP7B1 gene region do not affect natural resistance to HIV-1 infection.

Sironi M, Biasin M, Pontremoli C, Cagliani R, Saulle I, Trabattoni D, Vichi F, Lo Caputo S, Mazzotta F, Aguilar-Jimenez W, Rugeles MT, Cedeno S, Sanchez J, Brander C, Clerici M.

Retrovirology. 2015 Sep 24;12:80. doi: 10.1186/s12977-015-0206-0.

34.

Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function.

Shahid A, Olvera A, Anmole G, Kuang XT, Cotton LA, Plana M, Brander C, Brockman MA, Brumme ZL.

J Virol. 2015 Nov;89(22):11557-71. doi: 10.1128/JVI.01955-15. Epub 2015 Sep 9.

35.

T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.

Nowakowska J, Stuehler C, Egli A, Battegay M, Rauser G, Bantug GR, Brander C, Hess C, Khanna N.

Cytotherapy. 2015 Sep;17(9):1280-91. doi: 10.1016/j.jcyt.2015.06.003.

PMID:
26276009
36.

FARMS: A New Algorithm for Variable Selection.

Perez-Alvarez S, Gómez G, Brander C.

Biomed Res Int. 2015;2015:319797. doi: 10.1155/2015/319797. Epub 2015 Jul 26.

37.

Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture.

Guardo AC, Ruiz-Riol M, Fernández E, Maleno MJ, Bargalló ME, León A, Climent N, García F, Gatell JM, Brander C, Plana M.

AIDS. 2015 Jul 17;29(11):1309-18. doi: 10.1097/QAD.0000000000000728.

PMID:
26091301
38.

Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome.

Xu GJ, Kula T, Xu Q, Li MZ, Vernon SD, Ndung'u T, Ruxrungtham K, Sanchez J, Brander C, Chung RT, O'Connor KC, Walker B, Larman HB, Elledge SJ.

Science. 2015 Jun 5;348(6239):aaa0698. doi: 10.1126/science.aaa0698.

39.

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.

Mothe B, Hu X, Llano A, Rosati M, Olvera A, Kulkarni V, Valentin A, Alicea C, Pilkington GR, Sardesai NY, Rocafort M, Crespo M, Carrillo J, Marco A, Mullins JI, Dorrell L, Hanke T, Clotet B, Pavlakis GN, Felber BK, Brander C.

J Transl Med. 2015 Feb 15;13:60. doi: 10.1186/s12967-015-0392-5.

40.

Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.

Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández MÁ, Puertas MC, Carrillo J, Gonzalez N, León A, Pich J, Arnaiz JA, Gatell JM, Clotet B, Blanco J, Alcamí J, Martinez-Picado J, Alvarez-Fernández C, Sánchez-Palomino S, Guardo AC, Peña J, Benito JM, Rallón N, Gómez CE, Perdiguero B, García-Arriaza J, Esteban M, López Bernaldo de Quirós JC, Brander C, García F; RISVAC-03 Study Group.

J Antimicrob Chemother. 2015;70(6):1833-42. doi: 10.1093/jac/dkv046. Epub 2015 Feb 26.

PMID:
25724985
41.

Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.

Hancock G, Yang H, Yorke E, Wainwright E, Bourne V, Frisbee A, Payne TL, Berrong M, Ferrari G, Chopera D, Hanke T, Mothe B, Brander C, McElrath MJ, McMichael A, Goonetilleke N, Tomaras GD, Frahm N, Dorrell L.

PLoS Pathog. 2015 Feb 27;11(2):e1004658. doi: 10.1371/journal.ppat.1004658. eCollection 2015 Feb.

42.

The HLA-C*04: 01/KIR2DS4 gene combination and human leukocyte antigen alleles with high population frequency drive rate of HIV disease progression.

Olvera A, Pérez-Álvarez S, Ibarrondo J, Ganoza C, Lama JR, Lucchetti A, Cate S, Hildebrand W, Bernard N, Gomez L, Sanchez J, Brander C.

AIDS. 2015 Mar 13;29(5):507-17. doi: 10.1097/QAD.0000000000000574.

PMID:
25715101
43.

Immune screening identifies novel T cell targets encoded by antisense reading frames of HIV-1.

Berger CT, Llano A, Carlson JM, Brumme ZL, Brockman MA, Cedeño S, Harrigan PR, Kaufmann DE, Heckerman D, Meyerhans A, Brander C.

J Virol. 2015 Apr;89(7):4015-9. doi: 10.1128/JVI.03435-14. Epub 2015 Jan 14.

44.

HLA-B*35-PX and HLA-B*35-PY subtype differentiation does not predict observed differences in level of HIV control in a Peruvian MSM cohort.

Olvera A, Ganoza C, Pérez-Álvarez S, Hildebrand W, Sanchez J, Brander C.

AIDS. 2014 Sep 24;28(15):2323-5. doi: 10.1097/QAD.0000000000000403. No abstract available.

PMID:
25313587
45.

Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected.

Ruiz-Riol M, Llano A, Ibarrondo J, Zamarreño J, Yusim K, Bach V, Mothe B, Perez-Alvarez S, Fernandez MA, Requena G, Meulbroek M, Pujol F, Leon A, Cobarsi P, Korber BT, Clotet B, Ganoza C, Sanchez J, Coll J, Brander C.

J Infect Dis. 2015 Mar 15;211(6):936-46. doi: 10.1093/infdis/jiu534. Epub 2014 Sep 23.

46.

Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.

Yaciuk JC, Skaley M, Bardet W, Schafer F, Mojsilovic D, Cate S, Stewart CJ, McMurtrey C, Jackson KW, Buchli R, Olvera A, Cedeño S, Plana M, Mothe B, Brander C, West JT, Hildebrand WH.

J Virol. 2014 Nov;88(22):12992-3004. doi: 10.1128/JVI.01914-14. Epub 2014 Aug 27.

47.

Increased expression of SAMHD1 in a subset of HIV-1 elite controllers.

Riveira-Muñoz E, Ruiz A, Pauls E, Permanyer M, Badia R, Mothe B, Crespo M, Clotet B, Brander C, Ballana E, Esté JA.

J Antimicrob Chemother. 2014 Nov;69(11):3057-60. doi: 10.1093/jac/dku276. Epub 2014 Jul 25.

PMID:
25063780
48.

Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells.

Pauls E, Ruiz A, Badia R, Permanyer M, Gubern A, Riveira-Muñoz E, Torres-Torronteras J, Alvarez M, Mothe B, Brander C, Crespo M, Menéndez-Arias L, Clotet B, Keppler OT, Martí R, Posas F, Ballana E, Esté JA.

J Immunol. 2014 Aug 15;193(4):1988-97. doi: 10.4049/jimmunol.1400873. Epub 2014 Jul 11.

49.

HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans.

Bohne F, Londoño MC, Benítez C, Miquel R, Martínez-Llordella M, Russo C, Ortiz C, Bonaccorsi-Riani E, Brander C, Bauer T, Protzer U, Jaeckel E, Taubert R, Forns X, Navasa M, Berenguer M, Rimola A, Lozano JJ, Sánchez-Fueyo A.

Sci Transl Med. 2014 Jun 25;6(242):242ra81. doi: 10.1126/scitranslmed.3008793.

50.

Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03:04 and modulate primary natural killer cell function.

van Teijlingen NH, Hölzemer A, Körner C, García-Beltrán WF, Schafer JL, Fadda L, Suscovich TJ, Brander C, Carrington M, Evans DT, van Baarle D, Altfeld M.

AIDS. 2014 Jun 19;28(10):1399-408. doi: 10.1097/QAD.0000000000000284.

Supplemental Content

Loading ...
Support Center